HZA106827 (Weeks 1–12) REF | Placebo (n = 203) | FF 100 (n = 204) | FF/VI 100 (n = 201) |
---|---|---|---|
% of patients | 35% | 46% | 59% |
Odds Ratio (95% CI) | FF vs PbO: 2.29 (1.41, 3.73) | FF/VI vs PbO: 4.66 (2.84, 7.66) | |
Odds Ratio (95% CI) | FF/VI vs FF 100: 2.04 (1.29, 3.22) | ||
Time (days) when 50% of patients achieved 7 nights without symptoms | Did not occur during study | 70 | 44 |
HZA106863 (Weeks 1–12) REF |
FF 100
(n = 346) |
FF/VI 100
(n = 345) |
FF/VI 200
(n = 345) |
% of patients | 42% | 43% | 48% |
Odds Ratio (95% CI) | FF/VI 100 vs FF 100: 1.33 (0.93, 1.91) | FF/VI 200 vs FF/VI 100: 1.23 (0.87, 1.74) | |
Time (days) when 50% of patients achieved 7 nights without symptoms | 86 | 64 | 48 |
HZA106829 (Weeks 1–24) REF |
FF 200
(n = 193) |
FF/VI 200
(n = 197) |
FP 500
(n = 195) |
% of patients | 41% | 51% | 46% |
Odds Ratio (95% CI) | FF/VI 200 vs FF 200: 1.59 (0.99, 2.55) | ||
Odds Ratio (95% CI) | FF/VI 200 vs FP 500: 1.09 (0.69, 1.74) | ||
Time (days) when 50% of patients achieved 7 nights without symptoms | 111 | 72 | 84 |